These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38893720)

  • 21. Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
    Shiina K; Tomiyama H; Tanaka A; Imai T; Hisauchi I; Taguchi I; Sezai A; Toyoda S; Dohi K; Kamiya H; Kida K; Anzai T; Chikamori T; Node K;
    Hypertens Res; 2023 Feb; 46(2):495-506. PubMed ID: 36380202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.
    Tang J; Ye L; Yan Q; Zhang X; Wang L
    Front Pharmacol; 2022; 13():800490. PubMed ID: 35281930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
    Weeda ER; Cassarly C; Brinton DL; Shirley DW; Simpson KN
    J Diabetes Complications; 2019 Aug; 33(8):567-571. PubMed ID: 31176543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review.
    Miyamoto Y; Honda A; Yokose S; Nagata M; Miyamoto J
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis.
    Potier L; Mohammedi K; Velho G; Roussel R
    Cardiovasc Diabetol; 2021 May; 20(1):107. PubMed ID: 33985506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
    Scholtes RA; Muskiet MHA; van Baar MJB; Hesp AC; Greasley PJ; Hammarstedt A; Karlsson C; Hallow KM; Danser AHJ; Heerspink HJL; van Raalte DH
    Kidney Int Rep; 2022 May; 7(5):1084-1092. PubMed ID: 35570989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Inpatient Initiation of SGLT2 Inhibitors on Diuretic Requirements in Patients With Heart Failure.
    Cavagnini ME; Best EE; Skersick PT; Truitt KP; Musick KL; Mangum BR; Hollis IB; Rodgers JE
    J Pharm Pract; 2024 Jun; 37(3):683-689. PubMed ID: 37032494
    [No Abstract]   [Full Text] [Related]  

  • 30. Diuretics in States of Volume Overload: Core Curriculum 2022.
    Novak JE; Ellison DH
    Am J Kidney Dis; 2022 Aug; 80(2):264-276. PubMed ID: 35190215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study.
    Alsalem A; Alsultan MM; Alqarni F; Almangour A; Alsharekh L; Alenazi S; Alzahrani S; Almanqour RA; Alazmi A; Alzahrani A
    Front Pharmacol; 2024; 15():1366439. PubMed ID: 38628646
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy.
    Nashawi M; Ahmed MS; Amin T; Abualfoul M; Chilton R
    World J Cardiol; 2021 Dec; 13(12):676-694. PubMed ID: 35070111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment.
    Minatoguchi S; Hayashi H; Umeda R; Koide S; Hasegawa M; Tsuboi N
    CEN Case Rep; 2024 Oct; 13(5):419-424. PubMed ID: 38494546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study.
    Sawamura T; Karashima S; Nagase S; Nambo H; Shimizu E; Higashitani T; Aono D; Ohbatake A; Kometani M; Demura M; Furukawa K; Takeda Y; Yoneda T
    BMC Endocr Disord; 2020 Nov; 20(1):177. PubMed ID: 33256676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
    van Ruiten CC; Smits MM; Kok MD; Serné EH; van Raalte DH; Kramer MHH; Nieuwdorp M; IJzerman RG
    Cardiovasc Diabetol; 2022 Apr; 21(1):63. PubMed ID: 35484607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
    Masuda T; Watanabe Y; Fukuda K; Watanabe M; Onishi A; Ohara K; Imai T; Koepsell H; Muto S; Vallon V; Nagata D
    Am J Physiol Renal Physiol; 2018 Sep; 315(3):F653-F664. PubMed ID: 29790389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
    Isshiki M; Sakuma I; Hayashino Y; Sumita T; Hara K; Takahashi K; Shiojima I; Satoh-Asahara N; Kitazato H; Ito D; Saito D; Hatano M; Ikegami Y; Iida S; Shimada A; Noda M
    Endocr J; 2020 Nov; 67(11):1127-1138. PubMed ID: 32612066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.
    Carvalho PEP; Veiga TMA; Simões E Silva AC; Gewehr DM; Dagostin CS; Fernandes A; Nasi G; Cardoso R
    Clin Res Cardiol; 2023 Aug; 112(8):1044-1055. PubMed ID: 36592186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term outcomes after sodium-glucose cotransporter-2 inhibitor initiation in a cohort of heart failure patients.
    Pérez Martínez BO; Adie SK; Marshall VD; Konerman MC
    ESC Heart Fail; 2023 Oct; 10(5):3223-3226. PubMed ID: 37545470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists.
    Paul S
    Congest Heart Fail; 2002; 8(6):307-12. PubMed ID: 12461320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.